CRCS5
MCID: CLR080
MIFTS: 31

Colorectal Cancer 5 (CRCS5)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Colorectal Cancer 5

MalaCards integrated aliases for Colorectal Cancer 5:

Name: Colorectal Cancer 5 56 29
Colorectal Cancer, Susceptibility to, 5 56 13
Colorectal Cancer, Susceptibility to, on Chromosome 10 56
Colorectal Cancer on Chromosome 10 56
Crcs5 56

Classifications:



External Ids:

OMIM 56 612230

Summaries for Colorectal Cancer 5

MalaCards based summary : Colorectal Cancer 5, also known as colorectal cancer, susceptibility to, 5, is related to colorectal cancer, hereditary nonpolyposis, type 5 and colorectal cancer. An important gene associated with Colorectal Cancer 5 is CRCS5 (Colorectal Cancer, Susceptibility To, 5), and among its related pathways/superpathways is Angiogenesis (CST). The drugs Carboplatin and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and lung.

More information from OMIM: 612230

Related Diseases for Colorectal Cancer 5

Diseases in the Colorectal Cancer family:

Colorectal Cancer 1 Colorectal Cancer 2
Colorectal Cancer 3 Colorectal Cancer 5
Colorectal Cancer 6 Colorectal Cancer 7
Colorectal Cancer 8 Colorectal Cancer 9
Colorectal Cancer 10 Colorectal Cancer 11
Colorectal Cancer 12 Familial Colorectal Cancer
Familial Colorectal Cancer Type X

Diseases related to Colorectal Cancer 5 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 29)
# Related Disease Score Top Affiliating Genes
1 colorectal cancer, hereditary nonpolyposis, type 5 12.0
2 colorectal cancer 9.8
3 al amyloidosis 9.8 VWF ADAMTS13
4 thrombotic microangiopathy 9.8 VWF ADAMTS13
5 bombay phenotype 9.8 VWF ADAMTS13
6 splenic sequestration 9.8 VWF ADAMTS13
7 hypertensive retinopathy 9.8 VWF ADAMTS13
8 acquired von willebrand syndrome 9.8 VWF ADAMTS13
9 von willebrand disease, type 2 9.8 VWF ADAMTS13
10 von willebrand disease, type 3 9.8 VWF ADAMTS13
11 angiodysplasia 9.8 VWF ADAMTS13
12 primary thrombocytopenia 9.8 VWF ADAMTS13
13 autoimmune disease of cardiovascular system 9.8 VWF ADAMTS13
14 malignant hypertension 9.7 VWF ADAMTS13
15 inherited blood coagulation disease 9.7 VWF ADAMTS13
16 blood coagulation disease 9.7 VWF ADAMTS13
17 von willebrand's disease 9.7 VWF ADAMTS13
18 thrombotic thrombocytopenic purpura 9.7 VWF ADAMTS13
19 purpura 9.7 VWF ADAMTS13
20 coronary stenosis 9.7 VWF ADAMTS13
21 hemorrhagic disease 9.7 VWF ADAMTS13
22 hemolytic uremic syndrome, atypical 1 9.7 VWF ADAMTS13
23 disseminated intravascular coagulation 9.6 VWF ADAMTS13
24 antiphospholipid syndrome 9.6 VWF ADAMTS13
25 rectum cancer 9.6 TYMP MSH6
26 hemolytic-uremic syndrome 9.6 VWF ADAMTS13
27 blood platelet disease 9.6 VWF ADAMTS13
28 portal hypertension 9.5 VWF ADAMTS13
29 hellp syndrome 9.3 VWF ADAMTS13

Graphical network of the top 20 diseases related to Colorectal Cancer 5:



Diseases related to Colorectal Cancer 5

Symptoms & Phenotypes for Colorectal Cancer 5

Clinical features from OMIM:

612230

Drugs & Therapeutics for Colorectal Cancer 5

Drugs for Colorectal Cancer 5 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 40)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
2
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
3 Hormones Phase 3
4 Cola Phase 3
5 Calcium, Dietary Phase 3
6 Hematinics Phase 3
7
Calcium Nutraceutical Phase 3 7440-70-2 271
8
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
9
Artesunate Approved, Investigational Phase 2 88495-63-0 6917864 5464098
10
Fluorouracil Approved Phase 2 51-21-8 3385
11
leucovorin Approved Phase 2 58-05-9 6006 143
12
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
13
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
14
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
15
Bevacizumab Approved, Investigational Phase 2 216974-75-3
16
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
17 Anti-Infective Agents Phase 2
18 Anthelmintics Phase 2
19 Antiviral Agents Phase 2
20 Antiprotozoal Agents Phase 2
21 Antiparasitic Agents Phase 2
22 Artemisinins Phase 2
23 Artemisinine Phase 2
24 Antimalarials Phase 2
25 Vitamins Phase 2
26 Micronutrients Phase 2
27 Immunologic Factors Phase 2
28 Antidotes Phase 2
29 Vitamin B Complex Phase 2
30 Antineoplastic Agents, Immunological Phase 2
31 Folate Phase 2
32 Nutrients Phase 2
33 Immunosuppressive Agents Phase 2
34 Vitamin B9 Phase 2
35 Trace Elements Phase 2
36 Protective Agents Phase 2
37 Antimetabolites Phase 2
38 topoisomerase I inhibitors Phase 2
39 Angiogenesis Inhibitors Phase 2
40 Liver Extracts

Interventional clinical trials:

(show all 11)
# Name Status NCT ID Phase Drugs
1 A Multinational, Randomized, Phase III Study of FOLFIRI With/Without Bevacizumab Versus Irinotecan With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer Unknown status NCT03303495 Phase 3 CPT-11;5-FU Bolus;5-FU Infusion;l-LV (dl-LV)
2 5-Fluorouracil-Leucovorin With or Without Carboplatin as Adjuvant Treatment for Primary Dukes B2-C Colon Cancer; Chronomodulated Versus Standard Administration. A Multicenter Randomized Phase III Trial of the GRECCR-Belgium (Study 03). Unknown status NCT00046995 Phase 3 carboplatin;fluorouracil;leucovorin calcium
3 5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin) (FLOX Regimen), Given Continuously or Intermittently, in Combination With Cetuximab (Erbitux), in First-line Treatment of Metastatic Colorectal Cancer. A Phase III Multicenter Trial. Completed NCT00145314 Phase 3 FLOX (5-fluorouracil/folinic acid/oxaliplatin);FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab;FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab
4 Randomized Phase III Trial Comparing Adjuvant Oral UFT/LV to 5-FU/l-LV in Stage III Colorectal Cancer (JCOG-0205-MF) Completed NCT00190515 Phase 3 5FU+l-leucovorin;UFT+Leucovorin
5 A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer Completed NCT01996306 Phase 3 CPT-11 (Irinotecan);5-FU Bolus;5-FU Infusion;l-LV (dl-LV);CPT-11 (Irinotecan);Capecitabine
6 FOLFOX and Bevacizumab With or Without Irinotecan in First-line Treatment for Metastatic Colorectal Cancer. A Randomized Phase II Study Completed NCT01321957 Phase 2 Oxaliplatin, 5FU/LV, Bevacizumab;5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan
7 Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Metastatic Colorectal Cancer Recruiting NCT03530267 Phase 2 Aflibercept + mLV5FU2;mFOLFOX7
8 Phase II Randomised, Double Blind, Placebo Controlled Trial of Neoadjuvant Artesunate in Stage II/III Colorectal Cancer Recruiting NCT02633098 Phase 2 Artesunate 200mg;Placebo
9 Phase II Study Of Weekly Administration Oxaliplatin Plus 5-Fu/Lv (Aio Regimen) Plus Bevacizumab, Alternative With Irinotecan Plus 5-Fu/Lv(Aio Regimen) Plus Cetuximab, As Salvage Treatment In Pretreated Patients With Mcrc Terminated NCT00755118 Phase 2 Oxaliplatin;5-Fluorouracil;Leucovorin;Bevacizumab;Irinotecan;Cetuximab
10 Non-interventional Observational Study of Helical Tomotherapy for Oligometastatic Colorectal Cancer Completed NCT00807313
11 ObeSity Related Colorectal Adenoma Risk Recruiting NCT03663062

Search NIH Clinical Center for Colorectal Cancer 5

Genetic Tests for Colorectal Cancer 5

Genetic tests related to Colorectal Cancer 5:

# Genetic test Affiliating Genes
1 Colorectal Cancer 5 29

Anatomical Context for Colorectal Cancer 5

MalaCards organs/tissues related to Colorectal Cancer 5:

40
Colon, Liver, Lung, Thyroid, Testes

Publications for Colorectal Cancer 5

Articles related to Colorectal Cancer 5:

(show top 50) (show all 72)
# Title Authors PMID Year
1
A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. 56
18372905 2008
2
Changes in Colorectal Cancer 5-Year Survival Disparities in California, 1997-2014. 61
32371552 2020
3
Comparative lipidomics of 5-Fluorouracil-sensitive and -resistant colorectal cancer cells reveals altered sphingomyelin and ceramide controlled by acid sphingomyelinase (SMPD1). 61
32273521 2020
4
Sex-Dependent Adverse Drug Reactions to 5-Fluorouracil in Colorectal Cancer. 61
30930418 2019
5
In Vitro Anti-proliferative and Anti-invasive Effect of Polysaccharide-rich Extracts from Trametes Versicolor and Grifola Frondosa in Colon Cancer Cells. 61
30745803 2019
6
The features of adipose-derived stem cells in patients with inflammatory bowel diseases. 61
29027585 2018
7
Platelet Count, ADAMTS13 Activity, von Willebrand Factor Level and Survival in Patients with Colorectal Cancer: 5-Year Follow-up Study. 61
29304532 2018
8
Survival rates and predictors of survival among colorectal cancer patients in a Malaysian tertiary hospital. 61
28521746 2017
9
AKT is indispensable for coordinating Par-4/JNK cross talk in p21 downmodulation during ER stress. 61
28530706 2017
10
Perceived Barriers and Home Care Needs When Adapting to a Fecal Ostomy: A Phenomenological Study. 61
27564927 2017
11
Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis. 61
26676887 2016
12
Clinicopathological Characteristics and Prognosis of Colorectal Cancer in Chinese Adolescent Patients. 61
26612287 2015
13
A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma. 61
26333381 2015
14
[Total Pelvic Exenteration for Local Recurrence of Rectal Cancer Appearing 12 Years after Curative Operation--A Case Report]. 61
26805356 2015
15
[A Large Number of Circulating Tumor Cells(CTCs)Can Be Isolated from Samples Obtained by Using Leukapheresis Procedures]. 61
26469161 2015
16
A Model of Cancer Clinical Trial Decision-making Informed by African-American Cancer Patients. 61
25960945 2015
17
Colorectal cancer: 5 big questions. 61
25970454 2015
18
SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression. 61
25249558 2014
19
Fluorescent detection of peritoneal metastasis in human colorectal cancer using 5-aminolevulinic acid. 61
24821500 2014
20
A grey literature review of special events for promoting cancer screenings. 61
24942822 2014
21
Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. 61
23811785 2013
22
Genetic testing in the European Union: does economic evaluation matter? 61
21598012 2012
23
ATR-Chk1 signaling pathway and homologous recombinational repair protect cells from 5-fluorouracil cytotoxicity. 61
22188649 2012
24
The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the β-catenin signaling pathway. 61
22198215 2012
25
Outcome of sporadic adenomas and adenoma-like dysplasia in patients with ulcerative colitis undergoing polypectomy. 61
21416564 2012
26
Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. 61
21955833 2011
27
ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. 61
21652540 2011
28
Patient reported outcomes of symptoms and quality of life among cancer patients treated with palliative pelvic radiation: a pilot study. 61
21777440 2011
29
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. 61
21829508 2011
30
[Heterozygous carriers of Slavic mutation 657del5 of NBN gene in patients with colorectal cancer]. 61
21560448 2011
31
Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. 61
21067862 2011
32
Reactivation of IGFBP7 by DNA demethylation inhibits human colon cancer cell growth in vitro. 61
18981723 2008
33
Urinary total isothiocyanates and colorectal cancer: a prospective study of men in Shanghai, China. 61
18559550 2008
34
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. 61
18458053 2008
35
[Molecular targeted therapy in colorectal cancer]. 61
18202731 2008
36
The mesenteric and antimesenteric site of the tumor as possible prognostic factor in colorectal cancer: 5-year survival analysis. 61
18032025 2007
37
Study of colorectal cancer with Crohn's disease. 61
17970041 2007
38
Carbogen breathing differentially enhances blood plasma volume and 5-fluorouracil uptake in two murine colon tumor models with a distinct vascular structure. 61
16820094 2006
39
Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. 61
16299036 2006
40
Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma. 61
15245580 2004
41
Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. 61
14752071 2004
42
Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer. 61
14630248 2003
43
Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. 61
14598247 2003
44
[5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease]. 61
14714043 2003
45
Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer. 61
14519641 2003
46
A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines. 61
12792790 2003
47
Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors. 61
12655441 2003
48
[Comparative study of CEA antibody scan and computed tomography scan in the follow-up of patients with colorectal cancer]. 61
12236910 2002
49
[Hepatic serial resection. Portal vein resection followed by hepatic resection in second time]. 61
12731246 2002
50
Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer? 61
12087448 2002

Variations for Colorectal Cancer 5

Expression for Colorectal Cancer 5

Search GEO for disease gene expression data for Colorectal Cancer 5.

Pathways for Colorectal Cancer 5

Pathways related to Colorectal Cancer 5 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.57 VWF TYMP

GO Terms for Colorectal Cancer 5

Biological processes related to Colorectal Cancer 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet activation GO:0030168 9.16 VWF ADAMTS13
2 hemostasis GO:0007599 8.96 VWF ADAMTS13
3 pyrimidine nucleoside catabolic process GO:0046135 8.62 TYMP NT5E

Molecular functions related to Colorectal Cancer 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integrin binding GO:0005178 8.62 VWF ADAMTS13

Sources for Colorectal Cancer 5

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....